RESEARCH AND DEVELOPMENT
35 CANCER CONTROL 2021
would not be expected to occur if survival from that cancer in
that country were as high as in another country, typically in the
same world region.
The overall aim of VENUSCANCER is to provide actionable
evidence for health policies to reduce the burden of women's
cancers worldwide.
Protocol
The protocol for data collection has been developed in
collaboration with over 300 cancer registries worldwide. This
has been a major undertaking in its own right.
Three VENUSCANCER Working Group meetings to discuss
the protocol were held during major international conferences
in Arequipa, Peru (12 November 2018) at the International
Association of Cancer Registries (IACR) conference; in
Vancouver, Canada (12 June 2019), during the North American
Association of Central Cancer Registries (NAACCR), and in
Moscow, Russian Federation, during the Second International
Forum of Oncology and Radiology (23 September 2019). The
discussion focused on the first aim of the project, to collect
detailed demographic, biological and clinical data for women
diagnosed with breast, ovarian or cervical cancer during the most recent year for which data are available, and in as many
countries as possible.
The ERC Consolidator grant enabled support to be provided
for visa, travel, accommodation and conference fees for
six colleagues from LMICs (Brazil, Cuba, Nigeria, Russian
Federation, South Africa, and Thailand), who would not
otherwise have been able to participate in these meetings.
Three questionnaires were developed to help refine the
protocol for data collection. The questionnaires were designed:
J To identify cancer registries that are willing to contribute
to this challenging part of the VENUSCANCER project.
J To identify which registries have data at the required level
of completeness.
J To identify which registries are willing to increase the
completeness of their data.
J To select cancer registries in LMICs that would be eligible
for financial support for data collection.
The questionnaires were presented during the
VENUSCANCER Working Group meetings. My research team
helped our colleagues to complete the questionnaires, and we
discussed which variables were more likely to be collected and
BREAST CERVIX OVARY
0102030405060708090100
§ Morocco
§ Nigeria
§ Algeria
§ South Africa
§† Mali
Mauritius *
Martinique *
Costa Rica *
Argentina
Puerto Rico *
Peru
Ecuador
§ Chile
§ Brazil
Cuba *
§ Colombia
§ Guadeloupe *
United States
Canada
§ Cyprus *
Japan
Israel *
Korea *
§ Jordan *
Taiwan *
Hong Kong *
China
Turkey
Singapore *
Mongolia *
Kuwait *
§ Qatar *
§ Thailand
India
§ Malaysia
Iceland *
Sweden *
Finland *
Norway *
Portugal *
Malta *
France
Netherlands *
Belgium *
Switzerland
Denmark *
Germany
Italy
United Kingdom *
Spain
Austria *
Slovenia *
§ Latvia *
Ireland *
Czech Republic *
Croatia *
Bulgaria *
Estonia *
Poland *
Slovakia *
Romania
Lithuania *
Russian Federation
Gibraltar *
Australia *
New Zealand *
0102030405060708090 100
§ Algeria
§ Nigeria
§ South Africa
Mauritius *
§ Costa Rica *
Cuba *
Puerto Rico *
Brazil
Martinique *
Peru
§ Chile
Uruguay *
Argentina
Ecuador
§ Colombia
§ Guadeloupe *
Canada
United States
Korea *
§ Cyprus *
Japan
Taiwan *
China
Israel *
Hong Kong *
§† Qatar *
Singapore *
Turkey
India
§ Malaysia
Kuwait *
§ Jordan *
§ Thailand
† Iceland *
Norway *
Switzerland
Denmark *
Sweden *
Netherlands *
Finland *
Italy
Estonia *
Portugal *
Slovenia *
Belgium *
Romania
Germany
France
Spain
Austria *
United Kingdom *
Ireland *
Croatia *
Czech Republic *
Slovakia *
Lithuania *
Russian Federation
Malta *
§ Latvia *
Poland *
Bulgaria *
New Zealand *
Australia *
0102030405060708090100
§† South Africa
§ Algeria
§ Nigeria
Mauritius *
Costa Rica *
§ Cuba *
Argentina
Ecuador
§ Uruguay *
Puerto Rico *
§ Martinique *
Brazil
§ Colombia
§† Guadeloupe *
§ Chile
United States
Canada
Taiwan *
Korea *
§ Malaysia
§ Cyprus *
Japan
Israel *
Singapore *
China
Turkey
§ Qatar *
Thailand
Kuwait *
India
Sweden *
Norway *
§ Latvia *
Switzerland
Portugal *
France
Belgium *
Estonia *
Germany
Finland *
Austria *
Iceland *
Spain
Denmark *
Italy
Poland *
Netherlands *
Bulgaria *
§ Romania
Slovenia *
Czech Republic *
United Kingdom *
Croatia *
Lithuania *
Russian Federation
Slovakia *
Ireland *
Malta *
Australia *
New Zealand *
Data completeness
0
20
Less than 25% 25-49% 50-74% 75-100%
20 20
20
10
4
17
5
13 13
4
8 8
Figure 1: Global distribution by continent and country of age-standardised 5-year net survival for women (15-99 years) diagnosed during 2010-14 with breast,
cervical or ovarian cancer
*Data with 100% coverage of the national population.
†National estimate not age-standardised.
§National estimate flagged as less reliable because the only available estimates are from a registry or registries in this category.